Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
761 to 780 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. | Cancers (Basel) | 2022 | 36551707 | PubTator, text mining | PubMed |
| Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients. | Cancers (Basel) | 2022 | 36551643 | PubTator, text mining | PubMed |
| Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review. | Cancers (Basel) | 2022 | 36551605 | PubTator, text mining | PubMed |
| Cancer prevention in cancer predisposition syndromes: A protocol for testing the feasibility of building a hereditary cancer research registry and nurse navigator follow up model. | PLoS One | 2022 | 36548287 | PubTator, text mining | PubMed |
| "It Will Lead You to Make Better Decisions about Your Health"-A Focus Group and Survey Study on Women's Attitudes towards Risk-Based Breast Cancer Screening and Personalised Risk Assessments. | Curr Oncol | 2022 | 36547133 | PubTator, text mining | PubMed |
| Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. | BMC Cancer | 2022 | 36544182 | PubTator, text mining | PubMed |
| Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead. | Onco Targets Ther | 2022 | 36536949 | PubTator, text mining | PubMed |
| Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy. | Front Oncol | 2022 | 36531044 | PubTator, text mining | PubMed |
| Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis. | Front Oncol | 2022 | 36531003 | PubTator, text mining | PubMed |
| Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images. | Cell Rep Med | 2022 | 36516847 | PubTator, text mining | PubMed |
| Reduced LYNX1 expression in transcriptome of human iPSC-derived neural progenitors modeling fragile X syndrome. | Front Cell Dev Biol | 2022 | 36506088 | PubTator, text mining | PubMed |
| Management of metastatic castration-resistant prostate cancer in Middle East African countries: Challenges and strategic recommendations. | Urol Ann | 2022 | 36505997 | PubTator, text mining | PubMed |
| Advances in the understanding and treatment of Cutaneous T-cell Lymphoma. | Front Oncol | 2022 | 36505788 | PubTator, text mining | PubMed |
| DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. | Int J Mol Sci | 2022 | 36499000 | PubTator, text mining | PubMed |
| Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration. | Int J Mol Sci | 2022 | 36498861 | PubTator, text mining | PubMed |
| Splicing-Disrupting Mutations in Inherited Predisposition to Solid Pediatric Cancer. | Cancers (Basel) | 2022 | 36497448 | PubTator, text mining | PubMed |
| Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers. | Cancers (Basel) | 2022 | 36497436 | PubTator, text mining | PubMed |
| Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer. | Cancers (Basel) | 2022 | 36497408 | PubTator, text mining | PubMed |
| ATR Inhibitors in Platinum-Resistant Ovarian Cancer. | Cancers (Basel) | 2022 | 36497387 | PubTator, text mining | PubMed |
| Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. | Cancers (Basel) | 2022 | 36497275 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=39